• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

GSK spin­out NeRRe splits the pipeline, cre­ates its own spin­out

8 years ago
Startups

Oh, no we aren’t! Ab­b­Vie says it isn’t re­think­ing pric­ing pledge at all

8 years ago
Pharma

Small is big: Phar­ma’s R&D brain drain con­tin­ues as GSK’s Chris Car­pen­ter jumps to up­start Ru­bius

8 years ago
People

No time for for­mal­i­ties, Acor­da scraps FDA meet­ing in scram­ble to re-file CVT-301

8 years ago
Pharma

For­mer Za­cks biotech an­a­lyst Napo­dano charged with fraud af­ter set­tling with SEC on in­sid­er trad­ing cas­es

8 years ago
Pharma

EMA warns HQ move may cause ma­jor tur­moil, se­ri­ous­ly de­lay­ing new drug ap­provals

8 years ago
R&D
Pharma

New­ly de­buted biotech shoots for $40M IPO; In­tel­lia touts new an­i­mal da­ta on CRISPR/Cas9

8 years ago
News Briefing

In a damn­ing in­dict­ment, FDA re­view scorns PTC’s Duchenne drug for re­peat­ed fail­ures

8 years ago
Pharma

Next-gen CAR-T, TCR play­er Au­to­lus gains $80M for clin­i­cal tri­al work

8 years ago
Financing

Ax­o­van­t's lead Alzheimer's drug flops in PhI­II, end­ing an un­like­ly quest

8 years ago
R&D

Two young sci­en­tists bag $20M to per­fect their CRISPR at­tack on dis­ease-caus­ing bac­te­ria at up­start Eli­go

8 years ago
Financing
Startups

Geno­cea shelves its lead drug, slash­es staff and switch­es fo­cus to trendy neoanti­gens

8 years ago
R&D
Pharma

Pro­QR spot­lights the most en­cour­ag­ing re­sults from a mixed snap­shot of ef­fi­ca­cy for cys­tic fi­bro­sis

8 years ago
R&D

The top 5 trends in biotech - #3: High val­u­a­tions for at­trac­tive biotechs are a durable symp­tom of a thriv­ing ...

8 years ago

J&J lines up its 4-in-1 HIV pill for FDA be­hind ri­vals from Gilead, GSK

8 years ago
R&D

Spark re­cruits gene ther­a­py ex­pert Min­gozzi as new CSO; Fu­sion brings ven­ture round to $46M; Chi­na OKs Gilead’s ...

8 years ago
News Briefing

Pfiz­er spins off drug or­phans in­to a PhI­II-ready start­up backed by Bain to the tune of $103M

8 years ago
People
Financing

Puretech’s Gele­sis flunks the FDA’s key mea­sure of suc­cess for weight loss treat­ments

8 years ago
R&D

Vi­su­al­ize: What would these 11 biotech com­pa­nies look like with­out im­mi­grants?

8 years ago
R&D
Biotech Voices

Al­ler­gan caps a bad day with news the FDA has kicked back a sup­ple­men­tal ap­pli­ca­tion for cariprazine

8 years ago
Pharma

FDA spurns J&J's trou­bled rheuma­toid arthri­tis drug sirukum­ab

8 years ago
Pharma

How En­ter­prise cus­tomers can get End­points News in­to their Slack

8 years ago
Publisher's note

Ab­b­Vie part­ners on an Op­di­vo com­bo study with Bris­tol-My­ers; In­ter­cept tum­bles on FDA warn­ing

8 years ago
News Briefing

GSK vets Wit­ty and Slaoui find new roles in biotech as the great mi­gra­tion con­tin­ues

8 years ago
Peer Review
First page Previous page 1081108210831084108510861087 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.